Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
X4 Pharmaceuticals Inc (XFOR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.24+2.21%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for XFOR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
improve cash flow to reduce losses | A supporting condition in X4 Pharmaceuticals Inc's published investment case. The stated target is reduce negative free cash flow by at least 10% annually. | Improving | free cash flow worsens or stays flat over next year | Free cash flow: $-40.387M FY2026-Q2; GAAP. Published target: reduce negative free cash flow by at least 10% annually. Target and observation units differ. Aug 6, 2026-40,387,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making clinical-stage healthcare business, with its long-term thesis tied to development programs and future execution. The thesis state is intact, but confidence is medium and the risk label recently moved to high.
XFOR is valued at a premium to peers, and the evidence flags that premium as unjustified given fragile earnings quality and weak execution quality. The valuation model has low confidence, while optionality, or the possibility that development programs create future value, is the main source of uncertainty in what the market expects.
Near term, the latest reported quarter showed $2.4 million in revenue and an operating loss of $16.391 million, while the available evidence says recent performance remains in the top half of the industry. Management says it is focused on completing 4WARD enrollment and advancing mavorixafor, but supplied financials do not establish progress on either; the K2 facility adds financial flexibility, while losses remain. Guidance changes and weakening jobs data are risks, and the near-term miss watch is quiet despite the high-miss-rate industry and smaller-company profile.
The multi-year view hinges on progress in 4WARD and mavorixafor, with substantive clinical milestones not established in the supplied evidence. A guidance cut or continued weakness in jobs data would add pressure, while stronger earnings and guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, the thesis remains intact but fragile: clinical execution and financial flexibility must contend with ongoing losses, high risk, and a valuation premium the evidence calls unjustified. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
successful restructuring and leadership stability |
| A primary condition in X4 Pharmaceuticals Inc's published investment case. The stated target is stable leadership and no major negative changes next 12 months. |
| Intact |
| major executive departures or failed restructuring news |
No major executive departures or failed restructuring news reported CFO transition and board expansion noted; no major negative leadership changes or restructuring failures. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
reach at least $13 million revenue in 2025 | A primary condition in X4 Pharmaceuticals Inc's published investment case. The stated target is >=13 million USD. | Intact | revenue falls below $10 million in FY25 | Revenue: $2.8M FY2026-Q3; GAAP. Published target: >=13 million USD. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20262,800,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.75 → $-0.70 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.75 | $10,260,000 | 3 / 3 |
| 2026-07-25 | $-0.75 | $10,260,000 | 3 / 3 |
| 2026-07-26 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-07-27 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-07-28 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-07-29 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-07-30 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-07-31 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-01 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-02 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-03 | $-0.82 | $10,260,000 | 4 / 5 |
| 2026-08-04 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-05 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-06 | $-0.82 | $10,260,000 | 4 / 5 |
| 2026-08-08 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-09 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-10 | $-0.82 | $11,200,000 | 4 / 4 |
| 2026-08-12 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-13 | $-0.76 | $11,560,000 | 4 / 5 |
| 2026-08-14 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-15 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-16 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-17 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-18 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-19 | $-0.75 | $10,260,000 | 3 / 4 |
| 2026-08-20 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-21 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-22 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-23 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-24 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-25 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-26 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-27 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-28 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-29 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-30 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-08-31 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-01 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-02 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-03 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-04 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-05 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-06 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-07 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-08 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-09 | $-0.69 | $11,560,000 | 3 / 4 |
| 2026-09-10 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-11 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-12 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-13 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-14 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-15 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-16 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-17 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-18 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-19 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-20 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-21 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-22 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-23 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-24 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-25 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-26 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-27 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-28 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-29 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-09-30 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-01 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-02 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-03 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-04 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-05 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-06 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-07 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-08 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-09 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-10 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-11 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-12 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-13 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-14 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-15 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-16 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-17 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-18 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-19 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-20 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-21 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-22 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-23 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-24 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-25 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-26 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-27 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-28 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-29 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-30 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-10-31 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-11-01 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-11-02 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-11-03 | $-0.70 | $11,560,000 | 3 / 4 |
| 2026-11-04 | $-0.70 | $11,560,000 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.